Skip to main content
. 2020 Feb;61(2):242–248. doi: 10.2967/jnumed.119.230946

FIGURE 5.

FIGURE 5.

Therapeutic efficacy and safety of 131I-IITM in B16F10-bearing C57BL/6J mice. (A) Tumor volumes after treatment. Compared with the control (n = 6) and unlabeled FITM (n = 7) groups, 131I-IITM (n = 15) administration significantly inhibited B16F10 melanoma growth as indicated by tumor size. (B) Changes in body weight. Intergroup comparisons were performed using unpaired 2-tailed t tests. Asterisks indicate statistical significance (**P < 0.01). n.s. = no significance.